SCHEMBL3605183

SCHEMBL3605183

Cc1cnccc1-c1nc(Nc2cccc(Cl)c2)ncc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.49
SYK P43405 2/20 0.47
CDK1 P06493 2/20 0.47
ABL1 P00519 1/20 0.46
BCR P11274 1/20 0.46
PRKCA P17252 1/20 0.46
PRKCD Q05655 1/20 0.46
GRM5 P41594 3/20 0.45
MAOB P27338 2/20 0.45
MAOA P21397 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
CDK4 P11802 1/20 0.43
CDK2 P24941 1/20 0.43
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42
JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3592504 0.90 SYK (0.50) IGF1RSYKABL1BCRPRKCA
SCHEMBL3613115 0.86 SYK (0.47) IGF1RSYKABL1BCRPRKCA
SCHEMBL3610791 0.86 SYK (0.59) SYKCDK1ABL1BCRPRKCA
SCHEMBL3597071 0.84 PDGFRB (0.47) SYKABL1BCRPRKCAPRKCD
SCHEMBL3600187 0.80 ABL1 (0.65) ABL1BCRPRKCAPRKCDCDK4
SCHEMBL3449361 0.76 IGF1R (0.61) IGF1RSYKCDK1ABL1BCR
SCHEMBL3616045 0.74 SYK (0.52) IGF1RSYKCDK1ABL1BCR
SCHEMBL3348285 0.74 IGF1R (0.58) IGF1RSYKCDK1ABL1BCR
SCHEMBL14050650 0.71 IGF1R (0.79) IGF1RSYKCDK1CDK2JAK2
SCHEMBL2912369 0.70 SYK (0.56) IGF1RSYKABL1BCRPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
WO-2008079933-A2 HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS NOVARTIS AG (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048597-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 IGF1R 4144/4885SYK 2976/4885CDK1 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.